14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026
EVGN vs IMMX: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 17, 2026, Immix Biopharma, Inc. (IMMX) is the stronger overall head-to-head candidate over Evogene Ltd. (EVGN) in the Tradestie Institutional Equity Comparison Engine, winning 7–0 core matrix metrics and 2–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality). EVGN carries a Unified Composite Score of 44.1/100 (HOLD) at $0.34 (N/M Forward P/E, -858.2% operating margin), whereas IMMX carries 50.3/100 (HOLD) at $7.20 (N/M Forward P/E, 0.0% operating margin).
Technical & Structure Timing Caution: EVGN is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 44.5); meanwhile IMMX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 37.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on EVGN vs IMMX. Trailing 12-month operating profitability (EVGN -858.2% vs IMMX 0.0%) and valuation multiples (EVGN N/M vs IMMX N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $618.5M market capitalization and 0.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ EVGN vs IMMX Key Questions & Quantitative Answers
As of Nov 17, 2026, Immix Biopharma, Inc. (IMMX) is the stronger overall head-to-head candidate over Evogene Ltd. (EVGN) in the Tradestie Institutional Equity Comparison Engine, winning 7–0 core matrix metrics and 2–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality). EVGN carries a Unified Composite Score of 44.1/100 (HOLD) at $0.34 (N/M Forward P/E, -858.2% operating margin), whereas IMMX carries 50.3/100 (HOLD) at $7.20 (N/M Forward P/E, 0.0% operating margin). Technical & Structure Timing Caution: EVGN is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 44.5); meanwhile IMMX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 37.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
IMMX leads the Growth & Scale pillar: EVGN posts -60.7% YoY revenue growth and +0.0% YoY earnings growth on $1.7M TTM revenue (-67.6% gross margin, -858.2% operating margin), compared with IMMX at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, EVGN generates $1.7M in USD-normalized revenue versus N/A for IMMX. In operating R&D and SG&A reinvestment, EVGN deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for IMMX.
EVGN and IMMX trade at balanced relative valuation multiples. EVGN trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas IMMX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against EVGN (-182.8% ROE) versus IMMX (-27.0% ROE) capital efficiency.
In options market volatility and institutional positioning, EVGN carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.37β · 138% Vol realized risk). By comparison, IMMX carries 49.3% implied volatility (9th %ile, Compressed (<25th %ile)), a 0.05x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.83β · 83% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.